Rockwell Medical (RMTI) Stock Higher Today After FDA Approves Iron Replacement Drug

NEW YORK (TheStreet) -- Shares of Rockwell Medical are up 5.46% to $11.40 after the FDA approved the company's drug Triferic, which is used for treating iron loss in chronic kidney disease patients on dialysis, Reuters reports. Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron losses that occur during their dialysis treatment ...



from Google News, Yahoo! News, Wikinews, NY Times National News by search term http://ift.tt/1uRIQrf

via IFTTT